Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial – Bristol-Myers Squibb July 11, 2023
AstraZeneca: Tagrisso-chemo combo improved progression-free survival in late-stage lung cancer trial – Endpoints News – Endpoints News May 17, 2023
Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial – AstraZeneca May 17, 2023
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – Moderna Investor Relations April 16, 2023
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano – news.modernatx.com April 16, 2023
ARK: Survival Evolved to Ascend to PS5 in August, No Upgrade Path for Existing Owners – Push Square April 1, 2023
A couple on their honeymoon alleges a Hawaiian snorkeling company abandoned them in the ocean. A survival expert says they were lucky to survive. – Yahoo News March 6, 2023
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer – Merck March 1, 2023
Buffalo, New York, officials face questions about storm planning and response as harrowing accounts emerge of death and survival December 29, 2022December 29, 2022